Our Pricing

Weight Loss Injection Results: What UK Patients Can Realistically Expect

Published on: June 03, 2026

Understanding weight loss injection results UK patients can realistically achieve helps set appropriate expectations before starting treatment. At Cured Pharmacy, our UK-registered clinical team has supported thousands of patients through their weight management journey, and we've seen firsthand how clinical trial data translates into real-world outcomes. Here's what the evidence shows about tirzepatide, semaglutide, and liraglutide results over time.

Mounjaro (Tirzepatide) Results: The Clinical Evidence

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in the UK [1]. This dual mechanism produces significantly greater weight reduction compared to single-pathway treatments, with results that typically become noticeable within the first month of treatment.

In the landmark SURMOUNT-1 trial involving 2,539 adults with obesity, patients taking the 15mg maintenance dose achieved an average 22.5% total body weight reduction over 72 weeks [1]. This means a patient starting at 100kg could expect to lose approximately 22.5kg over 18 months, though individual results vary based on adherence, lifestyle factors, and metabolic response.

The weight loss trajectory with Mounjaro follows a predictable pattern: most patients lose 5-7% of their body weight in the first 12 weeks during dose escalation, with continued steady reduction through month 18 [1]. Approximately 91% of trial participants achieved at least 5% weight loss, whilst 57% achieved the clinically significant threshold of 20% or more [1].

Month-by-Month Mounjaro Results Timeline

Weeks 1-4: Initial appetite suppression begins, with 2-4% body weight reduction typical as you start on the 2.5mg dose. Weeks 5-12: Progressive weight loss of 5-8% as your dose increases to 5mg then 7.5mg. Months 4-6: Accelerated results with 10-15% total reduction on higher maintenance doses. Months 7-18: Continued steady loss reaching peak results of 15-22.5% depending on your prescribed maintenance dose [1]. These timelines assume consistent adherence to the prescribed regimen and lifestyle modifications recommended by your UK prescriber.

Wegovy (Semaglutide) Results: What the STEP Trials Show

Wegovy contains semaglutide, a GLP-1 receptor agonist that has been extensively studied in the STEP clinical trial programme [2]. As one of the first injectable weight loss treatments licensed in the UK, it has a robust evidence base demonstrating consistent, sustained results.

The STEP 1 trial followed 1,961 adults over 68 weeks and found that participants on the 2.4mg maintenance dose achieved an average 14.9% body weight reduction, compared to just 2.4% in the placebo group [2]. Approximately 86% of patients achieved at least 5% weight loss, whilst 50% achieved 15% or greater reduction [2].

Semaglutide results typically emerge more gradually than tirzepatide, with most patients experiencing noticeable appetite reduction within 2-3 weeks of starting treatment. The weight loss curve shows steady decline through month 16, after which most patients enter a maintenance phase where weight stabilises at the reduced level [2].

Saxenda (Liraglutide) Results: Daily Injection Outcomes

Saxenda contains liraglutide 3mg, administered as a daily injection rather than the weekly schedule used for newer GLP-1 treatments [3]. Whilst the daily regimen requires more commitment, clinical trials demonstrate meaningful weight reduction for appropriately selected patients.

The SCALE Obesity and Prediabetes trial tracked 3,731 participants over 56 weeks and found an average 8% body weight reduction in the liraglutide group versus 2.6% with placebo [3]. Approximately 63% of patients achieved at least 5% weight loss, and 33% achieved 10% or more [3].

Liraglutide results typically plateau earlier than weekly GLP-1 treatments, with most weight loss occurring in the first 6-9 months of treatment. The daily injection schedule can support better appetite control throughout the day, which some patients find beneficial for managing evening cravings and portion control [3].

Who Responds Best to Saxenda?

Clinical experience shows that patients who prefer daily medication routines, those with significant insulin resistance, and individuals who have previously responded well to other GLP-1 treatments tend to achieve optimal results with Saxenda. Your UK prescriber will assess whether daily or weekly injections better suit your lifestyle and clinical profile during your consultation.

Factors That Influence Your Individual Results

Whilst clinical trial data provides valuable benchmarks, individual weight loss injection results vary based on several key factors. Starting BMI plays a significant role—patients with higher baseline BMI typically achieve greater absolute weight loss, though percentage reductions remain consistent across BMI categories [1][2].

Adherence to the prescribed injection schedule is critical. Missing doses or inconsistent timing can significantly impact results, as these medications work by maintaining steady therapeutic levels in your system. Our clinical team at Cured Pharmacy provides ongoing support to help you establish reliable injection routines.

Lifestyle factors including dietary patterns, physical activity levels, sleep quality, and stress management all influence outcomes. Clinical trials showing the highest weight reductions included structured lifestyle interventions alongside medication [1][2][3]. The most successful patients typically combine their prescribed treatment with sustainable changes to eating habits and gradual increases in physical activity.

Metabolic factors such as insulin sensitivity, thyroid function, and genetic variations in GLP-1 receptor expression can affect individual response rates. Some patients experience rapid early results, whilst others see more gradual but sustained reduction over time. Both patterns can lead to successful long-term outcomes when treatment continues as prescribed.

Realistic Expectations: What Results Are Not Typical

It's important to understand what weight loss injection results are unlikely or unrealistic based on clinical evidence. Losing more than 1-1.5kg per week consistently is uncommon and may indicate insufficient caloric intake, which can compromise lean muscle mass and metabolic health [4].

Similarly, expecting immediate dramatic results in the first 2-3 weeks often leads to disappointment. These medications work by gradually reducing appetite and altering food preferences over time, not by blocking absorption or dramatically increasing metabolism. Early results of 2-4% body weight reduction in the first month represent excellent progress [1][2].

Weight loss is rarely linear—most patients experience weeks of steady reduction followed by plateaus lasting 2-4 weeks before loss resumes. These plateaus are a normal part of metabolic adaptation and don't indicate treatment failure. Continuing your prescribed regimen through plateaus is essential for achieving long-term results.

Finally, whilst clinical trials show impressive average outcomes, approximately 10-15% of patients don't achieve the 5% weight loss threshold considered clinically significant [1][2][3]. If you're not seeing expected results after 3-4 months at your maintenance dose, your UK prescriber may recommend adjusting your treatment plan or investigating underlying factors affecting response.

When to Consult Your Prescriber About Results

Contact your UK clinical team if you experience less than 2% weight loss in your first 8 weeks, sudden weight regain of more than 2kg whilst adherent to treatment, or concerning side effects that interfere with consistent dosing. Early intervention can help optimise your treatment plan and identify any barriers to successful outcomes.

Maintaining Your Weight Loss Results Long-Term

Clinical trial extension studies reveal important insights about maintaining weight loss injection results after achieving your target. The SURMOUNT-4 trial demonstrated that patients who discontinued tirzepatide after achieving significant weight loss regained an average 14% of their body weight over the following year, whilst those who continued treatment maintained their reduced weight [5].

This data suggests that for most patients, ongoing treatment is necessary to sustain results—similar to how blood pressure or cholesterol medications require continued use to maintain therapeutic effects. Weight management is a chronic condition requiring long-term medical support, not a short-term intervention [5].

Transitioning to a maintenance phase typically occurs after 12-18 months once you've achieved your clinical goals. Some patients maintain results on lower doses than their peak treatment dose, whilst others require consistent dosing to prevent regain. Your UK prescriber will work with you to determine the optimal long-term strategy based on your individual response.

Building sustainable lifestyle habits during your active weight loss phase significantly improves long-term maintenance success. Patients who establish regular physical activity routines, develop mindful eating practices, and address psychological factors related to food relationships show better weight stability even if they eventually discontinue medication [4][5].

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
4. Ryan, D. H., & Yockey, S. R. (2017). Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over. Current Obesity Reports, 6(2), 187–194. https://doi.org/10.1007/s13679-017-0262-y [accessed 13 August 2026]
5. Aronne, L. J., Sattar, N., Horn, D. B., et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 331(1), 38–48. https://doi.org/10.1001/jama.2023.24945 [accessed 13 August 2026]

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results vary and depend on multiple factors including adherence, lifestyle modifications, and metabolic response. Past clinical trial results do not guarantee individual outcomes.